CSL Limited

72 patents currently held · Updated Nov 14, 2026

17 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Jan 2, 2027
2 fees due Feb 15 to 22, 2027 · next Feb 15
3 fees due Mar 8 to 24, 2027 · next Mar 8
2 fees due May 3 to 24, 2027 · next May 3
3 fees due Jun 12 to 15, 2027 · next Jun 12
2 fees due Jul 21 to 28, 2027 · next Jul 21
1 fee due Sep 30, 2027
The maintenance fee for Reconstructed HDL formulation (US 10,603,355) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
2 fees due Oct 16 to 21, 2027 · next Oct 16

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,150,619	Method of elicting or inducing an immune response In force Term ends Aug 31, 2027 · From the USPTO record	In force	Term ends Aug 31, 2027	From the USPTO record
US 7,754,213	High Affinity Antibody Antagonists of INTERLEUKIN-13 Receptor Alpha 1 In force Term ends Oct 19, 2027 · High confidence	In force	Term ends Oct 19, 2027	High confidence
US 8,568,722	High Affinity Antibody Antagonists of INTERLEUKIN-13 Receptor Alpha 1 In force Term ends Oct 19, 2027 · High confidence	In force	Term ends Oct 19, 2027	High confidence
US 9,371,388	High Affinity Antibody Antagonists of INTERLEUKIN-13 Receptor Alpha 1 In force Term ends Oct 19, 2027 · High confidence	In force	Term ends Oct 19, 2027	High confidence
US 9,777,062	High Affinity Antibody Antagonists of INTERLEUKIN-13 Receptor Alpha 1 In force Term ends Oct 19, 2027 · High confidence	In force	Term ends Oct 19, 2027	High confidence
US 10,106,617	High Affinity Antibody Antagonists of INTERLEUKIN-13 Receptor Alpha 1 In force Term ends Oct 19, 2027 · High confidence	In force	Term ends Oct 19, 2027	High confidence
US 7,956,035	Treatment of endothelial dysfunction in diabetic patients In force Term ends Oct 23, 2027 · From the USPTO record	In force	Term ends Oct 23, 2027	From the USPTO record
US 8,557,962	Treatment of endothelial dysfunction in diabetic patients In force Term ends Nov 4, 2027 · From the USPTO record	In force	Term ends Nov 4, 2027	From the USPTO record
US 9,376,682	Method of treating pulmonary disease by administering an antibody to G-CSF In force Term ends Jan 26, 2028 · From the USPTO record	In force	Term ends Jan 26, 2028	From the USPTO record
US 8,182,814	Methods of Treating Inflammatory Airway Conditions by Inhibition of IL-11 Activity In force Term ends Oct 23, 2028 · High confidence	In force	Term ends Oct 23, 2028	High confidence

10 of 72 patents shown.

Pro members see all 72.

Pro members: see all 72 patents

Also on record, not counted in the 72: 17 patents in force now held by others · 30 lapsed for an unpaid fee · 41 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 19 abandoned · 52 no status recorded

List them